



A34

1

SEQUENCE LISTING

<110> LIPTON, JAMES M.

<120> A COMPOUND AND METHOD OF TREATMENT FOR FUNGAL PATHOLOGIES
OF THE ORAL CAVITY

<130> 54275.8010.US00

<140> 09/774,282

<141> 2001-01-29

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> n-term may or may not be acetylated

<220>

<223> c-term may or may not be amidated

<400> 1

Lys Pro Val

1

<210> 2

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<223> n-term may or may not be acetylated

<220>

<223> c-term may or may not be amidated

<400> 2

Met Glu His Phe Arg Trp Gly

1

5

<210> 3

<211> 8

<212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic peptide

<220>
 <223> n-term may or may not be acetylated

<220>
 <223> c-term may or may not be amidated

<400> 3
 His Phe Arg Trp Gly Lys Pro Val
 1 5

<210> 4
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic peptide

<220>
 <223> n-term may or may not be acetylated

<220>
 <223> c-term may or may not be amidated

<400> 4
 Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val
 1 5 10

<210> 5
 <211> 39
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic peptide

<400> 5
 Ser Tyr Ser Met Glu His Phe Arg Trp Gly Lys Pro Val Gly Lys Lys
 1 5 10 15

Arg Arg Pro Val Leu Val Tyr Pro Ala Gly Glu Asp Asp Glu Ala Ser
 20 25 30

Glu Ala Phe Pro Leu Glu Phe
 35

<210> 6
 <211> 22
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 peptide

<400> 6
 Arg Pro Val Leu Val Tyr Pro Ala Gly Glu Asp Asp Glu Ala Ser Glu
 1 5 10 15
 Ala Phe Pro Leu Glu Phe
 20

<210> 7

<400> 7
 000

<210> 8
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 peptide

<220>
 <223> see specification as filed for detailed description of
 modifications and preferred embodiments

<400> 8
 Cys Lys Pro Val
 1

<210> 9
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 peptide

<220>
 <221> MOD_RES
 <222> (4)
 <223> Nle

<220>
 <221> MOD_RES

Cont
R34
<222> (7)
<223> D-Phe

<400> 9
Ser Tyr Ser Xaa Glu His Phe Arg Trp Gly Lys Pro Val
1 5 10

<210> 10
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (1)
<223> D-Lys

<220>
<223> c-term amidation

<400> 10
Lys Pro Val
1
